Lung clearance index: Evidence for use in clinical trials in cystic fibrosis

Lisa Kent, P. Reix, J.A. Innes, S. Zielen, M. Le Bourgeois, C. Braggion, S. Lever, H.G.M. Arets, K. Brownlee, J. M. Bradley, K. Bayfield, K. O'Neill, D. Savi, D. Bilton, A. Lindblad, J.C. Davies, I. Sermet, K. De Boeck

Research output: Contribution to journalArticlepeer-review

127 Citations (Scopus)
513 Downloads (Pure)


The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of clinical endpoints with regard to their use in multicentre clinical trials in CF. The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status. It was concluded that LCI has an attractive feasibility and clinimetric properties profile and is particularly indicated for multicentre trials in young children with CF and patients with early or mild CF lung disease. This is the first article to collate the literature in this manner and support the use of LCI in clinical trials in CF.
Original languageEnglish
Pages (from-to)123-138
Number of pages16
JournalJournal of Cystic Fibrosis
Issue number2
Early online date05 Dec 2013
Publication statusPublished - Mar 2014


Dive into the research topics of 'Lung clearance index: Evidence for use in clinical trials in cystic fibrosis'. Together they form a unique fingerprint.

Cite this